Skip to main content
. 2026 Apr 13;16(8):101635. doi: 10.1016/j.jpha.2026.101635

Fig. 7.

Fig. 7

Inhibition of ferroptosis and improvement of human umbilical vein endothelial cells (HUVECs) function by diosgenin (DG) are regulated by small interfering RNA of sirtuin 6 (Sirt6-siRNA). After Sirt6-siRNA used, angiogenesis-related proteins were detected. (A, B) Western blot (WB) (A) and quantitative analysis (B) of sirtuin 6 (Sirt6) protein expression in differentially treated HUVECs. (C, D) Evaluation of HUVECs migration (C) and quantitative analysis (D) using the transwell migration assay. (E, F) The scratches assay (E) and quantitative analysis (F) of HUVECs. (G, H) Evaluation of HUVECs angiogenesis (G) and quantitative analysis (H) using the tube formation assay. (I, J) WB (I) and quantitative analysis (J) of cluster of differentiation 31 (CD31), α-smooth muscle actin (α-SMA), and vascular endothelial growth factor A (VEGF-A) protein expression in differentially treated HUVECs. (K, L) WB (K) and quantitative analysis (L) of nuclear-Nrf2 (n-Nrf2) expression in differentially treated HUVECs. (M−O) WB (M) and quantitative analysis of phosphorylated-Sirt6 (p-Sirt6) (N), kelch-like ECH-associated protein 1 (Keap1), solute carrier family 7 member 11 (SLC7A11), and glutathione peroxidase 4 (GPX4) protein expression (O) in differentially treated HUVECs. Data are presented as the mean ± standard deviation (SD) from 5 independent experiments (n = 5). Statistical significance is denoted as ∗∗∗P < 0.001; ns indicates no significant difference. Nc: negative control.